Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1990 1
1992 1
1993 5
1994 14
1995 15
1996 12
1997 41
1998 53
1999 58
2000 66
2001 35
2002 44
2003 37
2004 10
2005 5
2006 9
2007 9
2008 7
2009 5
2010 6
2011 9
2012 3
2013 2
2014 1
2016 1
2017 3
2018 2
2019 1
2020 3
2021 4
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 9671000

458 results

Results by year

Filters applied: . Clear all
Page 1
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. Ghaffari S, et al. Am J Cardiol. 1998 Jul 1;82(1):7-12. doi: 10.1016/s0002-9149(98)00238-0. Am J Cardiol. 1998. PMID: 9671000 Clinical Trial.
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Lincoff AM, et al. Circulation. 1999 Apr 20;99(15):1951-8. doi: 10.1161/01.cir.99.15.1951. Circulation. 1999. PMID: 10208997 Clinical Trial.
Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Lefkovits J, et al. J Am Coll Cardiol. 1996 Oct;28(4):849-55. doi: 10.1016/s0735-1097(96)00239-2. J Am Coll Cardiol. 1996. PMID: 8837559 Free article. Clinical Trial.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ. Lefkovits J, et al. Am J Cardiol. 1996 May 15;77(12):1045-51. doi: 10.1016/s0002-9149(96)00128-2. Am J Cardiol. 1996. PMID: 8644655 Clinical Trial.
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ. Lincoff AM, et al. Circulation. 2000 Dec 12;102(24):2923-9. doi: 10.1161/01.cir.102.24.2923. Circulation. 2000. PMID: 11113041 Clinical Trial.
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Cho L, et al. J Am Coll Cardiol. 2000 Aug;36(2):381-6. doi: 10.1016/s0735-1097(00)00746-4. J Am Coll Cardiol. 2000. PMID: 10933346 Free article.
458 results